Clinical Trials

View our

CLINICAL TRIALS

Research continues to show that patients treated on clinical trials have the best outcomes. As a cutting-edge research program and member of the Children’s Oncology Group, the Pediatric Blood and Marrow Transplantation Consortium, and the leader of several clinical trial consortiums, the Children and Adolescent Cancer and Blood Diseases Center is proud to offer our patients the latest in clinical trials for their diagnosis.

Patients treated by our program benefit from our research affiliation with New York Medical College as well as a dedicated children’s research hospital, the Maria Fareri Children’s Hospital at Westchester Medical Center. We offer access to investigator-initiated trials developed right here at our institution, as well as multi-center clinical trials from around the globe that are improving upon the standard of care with cutting-edge treatments that are more effective, less toxic, and ultimately, the best in class. Additionally, our state-of-the-art Cellular Tissue and Engineering Laboratory at Westchester Medical Center and the Pediatric Cancer Research Foundation Laboratory at New York Medical College, are bringing bench-to-bedside breakthroughs in treatment for cancer and hematological disorders, transforming the speed at which research findings are making their way into patient care.

Patients do not have to travel far from home to access state of the art clinical trials. And because all of our clinical research is overseen by New York Medical College’s Oncology Institutional Review Board, patients know that our trials have passed rigorous reviews and meet the highest ethical standards involving research involving children and adults alike.

To learn more about some of the clinical trials offered at the Childhood and Adolescent Cancer and Blood Diseases Center, please click on the diseases below, or contact us 914-493-7997.

Acute Lymphoblastic Leukemia

Clinical Trials for

Acute Lymphoblastic Leukemia

AALL1731 – A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
ACCL1931, A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
PEPN22P1: A Pharmacokinetic Study of VinCRIStine in Infants Dosed According to BSA-Banded Infant Dosing Tables and Older Children Dosed by Traditional BSA Methods
ASCT2031, A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLAHaploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)
NYMC-598, A Phase II Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (T ALL/T LLy) (ALLO-T-DART) (NCT04972942)
NYMC 588 – Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing alpha/beta T cell and CD19+ B Cell Depletion: NYMC 588
NYMC 585 – END RAD: A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative

Acute Myeloid Leukemia

Clinical Trials for

Acute Myeloid Leukemia

ADVL1822: A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and as a Single-Agent Maintenance Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years and Young Adults Aged up to 21 Years with FLT3 ITD mutations https://clinicaltrials.gov/ct2/show/NCT03793478?term=Quizartinib&cond=Acute+Myeloid+Leukemia&cntry=US&draw=3&rank=9
AAML1831 CIRB, A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy
ASCT2031, A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLAHaploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)
NYMC 605: A Phase II Pilot Study of Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults with High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study (EXCEL Trial)
NYMC 588 – Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing alpha/beta T cell and CD19+ B Cell Depletion: NYMC 588

Acute Promyelocytic Leukemia

Clinical Trials for

Acute Promyelocytic Leukemia

Aplastic Anemia

Clinical Trials for

Aplastic Anemia

10-CBA – A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NYMC 588 – Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing alpha/beta T cell and CD19+ B Cell Depletion: NYMC 588

Brain Tumors

Clinical Trials for

Brain Tumors

ACNS1422 – A Phase 2 Study of Reduce Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
ACNS1831 – A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
ACNS1833- A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
NYMC 189 – HEAD START 4 PROTOCOL: Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Embryonal Tumors. Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Randomization to either Single-Cycle or to Three Sequential Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue
NYMC 195 – A Phase 1 Study of Vorinostat in Combination with Vincristine, Irinotecan and Temozolomide in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors and CNS Malignancies
ACNS1931, A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination withVinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas(LGGs) Lacking BRAFV600E or IDH1 Mutations
ACNS2021, A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System
ACNS2031:A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features
PEPN2111, A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma

Cellular Therapies

Clinical Trials for

Cellular Therapies

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
NYMC 597 – A Phase II Open-Label Randomized Study of Anti-Viral Antibiotic Therapy with and without Familial (Maternal) Cytomegalovirus (CMV) Cytotoxic T Lymphocytes (CTLs) in Neonates with Moderate/Severe Maternal Acquired CMV Infection
NYMC 608: Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
NYMC 604: A Pilot Study of SARS-CoV-2 Specific Cytotoxic T Lymphocytes (SARS-CoV-2-CTLs) for Treatment of Mild to Moderate Coronavirus Disease 2019 (COVID-19)
NYMC-598, A Phase II Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (T ALL/T LLy) (ALLO-T-DART) (NCT04972942)
NYMC 588 – Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing alpha/beta T cell and CD19+ B Cell Depletion: NYMC 588
NYMC 585 – END RAD: A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
ASCT2031, A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLAHaploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)
NYMC 592: Safety and tolerability of myeloablative conditioning and autologous stem cell transplantation followed by Polatuzumab Vedotin (PV) immunoconjugate therapy in patients with B-cell non-Hodgkin and Hodgkin lymphoma

Graft VS Host Disease

Clinical Trials for

Graft vs Host Disease

NYMC 613: KD025-218,A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Participants with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

Hodgkin Lymphoma

Clinical Trials for

Hodgkins Lymphoma

NYMC 208: Reducing the Burden of Oncologic Chemoradiotherapy And Radiation Exposure from Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults with Lymphoma (RADICAL)
NYMC 592: Safety and tolerability of myeloablative conditioning and autologous stem cell transplantation followed by Polatuzumab Vedotin (PV) immunoconjugate therapy in patients with B-cell non-Hodgkin and Hodgkin lymphoma

Langerhans Histiocytosis

Clinical Trials for

Langerhans Histiocytosis

ANHL2121:Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis

Non-Hodgkin Lymphoma

Clinical Trials for

Non-Hodgkins Lymphoma (Burkitt, Large Cell, Lymphoblastic, Anaplastic)

NYMC 166 – ImmunoChemotherapy with Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in children, adolescents and young adults with recurrent refractory CD20+ mature B-NHL
NYMC 172 – Childhood, Adolescent, and Young Adult (CAYA) Lymphoma/Leukemia Tissue Banking and Biorepository Center (BRC): CAYA L/L BRC
NYMC 575: Induction Chemo-Immunotherapy Followed by Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-cell or NK Lymphoma/Leukemia https://clinicaltrials.gov/ct2/show/NCT03719105?term=NCT03719105&draw=2&rank=1
NYMC 208: Reducing the Burden of Oncologic Chemoradiotherapy And Radiation Exposure from Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults with Lymphoma (RADICAL)
NYMC 592: Safety and tolerability of myeloablative conditioning and autologous stem cell transplantation followed by Polatuzumab Vedotin (PV) immunoconjugate therapy in patients with B-cell non-Hodgkin and Hodgkin lymphoma
PEPN2111, A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
NYMC 227: A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
NYMC 226 :A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms
ANHL1931, A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with
Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
NYMC 225: A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (003)
NYMC 224: A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of
Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (004)
NYMC-598, A Phase II Trial of Targeted Immunotherapy with Daratumumab Following Myeloablative Total Body Irradiation (TBI)-Based Conditioning and Allogeneic Hematopoietic Cell Transplantation in Children, Adolescents and Young Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (T ALL/T LLy) (ALLO-T-DART) (NCT04972942)
NYMC 588 – Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing alpha/beta T cell and CD19+ B Cell Depletion: NYMC 588

Novel Therapeutics

Clinical Trials for

Novel Therapeutics

APEC1621SC – NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
NYMC 579 A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection with Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs) in Children, Adolescents and Young Adult Recipients
NYMC 580 A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections with Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients
NYMC 581 A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection with Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients
NYMC544 – A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
NYMC 590 A Pilot Study in the Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients https://clinicaltrials.gov/ct2/show/NCT04197596?term=NCT04197596&draw=2&rank=1
NYMC 588 Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion – https://clinicaltrials.gov/ct2/show/NCT04099966?term=NYMC+588&draw=2&rank=1
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
PEPN2121: A Phase 1/2 Study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
NYMC 610: A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy
PEPN2111, A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
NYMC 227: A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
NYMC 226: A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms
NYMC 225: A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (003)
NYMC 224: A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of
Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (004)
PEP1924-A PHASE 2 STUDY OF DS-8201A (NSC# 807708, IND# 153036) IN ADOLESCENTS, OR
YOUNG ADULTS WITH RECURRENT HER2+ OSTEOSARCOMA
NYMC 604: A Pilot Study of SARS-CoV-2 Specific Cytotoxic T Lymphocytes (SARS-CoV-2-CTLs) for Treatment of Mild to Moderate Coronavirus Disease 2019 (COVID-19)
NYMC 212: A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF RAVULIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WHO HAVE THROMBOTIC MICROANGIOPATHY (TMA) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
NYMC 211: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients with Solid Tumors or Lymphomas and Treated with Myelosuppressive Chemotherapy
NYMC 195 A Phase 1 Study of Vorinostat in Combination with Vincristine, Irinotecan and Temozolomide in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors and CNS Malignancies
NYMC600:A Phase II Intrapatient Open-Label Dose Escalation Trial of Defibrotide in Hematopoietic Cell Transplantation (HCT) Recipients with Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated with either Renal and/or Pulmonary Dysfunction with Either Refractory or Progressive Disease Following Defibrotide Therapy

Sickle Cell Disease

Clinical Trials for

Sickle Cell Disease

NYMC 556 – Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients with Sickle Cell Disease and Thalassemia
NYMC-571 The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease Following Myeloablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback (IND 127812)
NYMC 588 – Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing alpha/beta T cell and CD19+ B Cell Depletion: NYMC 588

Solid Tumors

Clinical Trials for

Solid Tumors

A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
ANBL1531 – A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
ANBL1232 – Utilizing Response & Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
AREN03B2 – Renal Tumors Classification, Biology, and Banking Study
ARST1431 – A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
CCG4914L – National Wilms Tumor Late Effects Study
AGCT1531 – A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532 – A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors
AHEP1531–
NYMC 195 – A Phase 1 Study of Vorinostat in Combination with Vincristine, Irinotecan and Temozolomide in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors and CNS Malignancies
AHEP1531 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
PEPN2121: A Phase 1/2 Study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
PEPN2111, A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma
AOST2031, A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
ACNS2021, A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor
ARST2031, A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC)
Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patientswith High Risk Rhabdomyosarcoma (HR-RMS).
PEP1924-A PHASE 2 STUDY OF DS-8201A (NSC# 807708, IND# 153036) IN ADOLESCENTS, OR YOUNG ADULTS WITH RECURRENT HER2+ OSTEOSARCOMA
AREN1921, Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
J12106 A Phase II Trial of Reduced Intensity Conditioning of Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplant for High-risk Solid Tumors
NYMC 211: A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients with Solid Tumors or Lymphomas and Treated with Myelosuppressive Chemotherapy
J17124 Single-arm, open-label, phase 1b/2 trial of Nivolumab therapy following partially HLA mismatched (haploidentical) bone marrow transplant in children and young adults with high risk, recurrent or refractory solid tumors
NYMC 597: A Phase II Open-Label Randomized Study of Anti-Viral Antibiotic Therapy with and without Familial (Maternal) Cytomegalovirus (CMV) Cytotoxic T Lymphocytes (CTLs) in Neonates with Moderate/Severe Maternal Acquired CMV Infection

NYMC 163 – Non-Graft Versus Host Disease Skin Changes in Pediatrics Hematopoietic Stem Cell Recipients
NYMC 557 – NMDP – Protocol For A Research Sample Repository for Allogeneic Hematopoeitic Stem Cell Transplantation and Marrow Toxic Injuries
NYMC 565 – NMDP/CIBMTR – Protocol For A Research Database for Hematopoeitic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
NYMC 569 – National Cord Blood Program IND Clinical Trial Agreement
NYMC 235 : PIDTC 6908: Analysis of Autoinflammation in Chronic Granulomatous Disease Patients Undergoing Hematopoietic Cell Transplantation or Gene Therapy
NYMC 234: PIDTC 6907: Severe Combined Immune Deficiency: Prospective and Longitudinal Study of Genotypes, Management and Outcomes
NYMC 610: A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy
NYMC 212: A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY OF RAVULIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WHO HAVE THROMBOTIC MICROANGIOPATHY (TMA) AFTER HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
PBMTC 1801 (CSIDE) – A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRαβ+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)

Clinical Trials

CLINICAL TRIALS

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Acute Promyelocytic Leukemia

Aplastic Anemia

Brain Tumors

Cellular Therapies

Graft VS Host Disease

Hodgkin Lymphoma

Langerhans Histiocytosis

Non-Hodgkin Lymphoma

Novel Therapeutics

Sickle Cell Disease

Solid Tumors

Thalassemia

Wellness and Survivorship

Biology/Tumor Banking

Other